Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
December 17, 2014
Wednesday’s RegMed rhythms: should we drive on a reflated tire with a nail puncture?
December 16, 2014
RegMed, the cheap get cheaper. Where’s The Alliance for Regenerative Medicine (ARM) in support of the sector – when it is MOST needed?
December 16, 2014
Tuesday’s RegMed rhythms: exhausted, confused and anxious
December 15, 2014
RegMed: Pathetic doesn’t come close to describing today’s performance
December 15, 2014
Monday’s RegMed rhythms: the good, the bad and the ugly – volatility!
December 12, 2014
RegMed, capitulation bounce upward for NeoStem (NBS) and Organovo (ONVO)
December 12, 2014
Friday’s RegMed rhythms: ½ full and ½ empty
December 11, 2014
RegMed closes UP with a lot of selling pressure as afternoon session progressed
December 11, 2014
Thursday’s RegMed rhythms: an oversold sector begets a purchase “page” not an investing “chapter”
December 11, 2014
Verastem (VSTM) releases data – BUY
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.